Floatz logo

Adavosertib

Female Reproductive Organ Cancer

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

50 Active assets in the Female Reproductive Organ Cancer cohort.

Asset / SponsorPhaseRating
DOXORUBICIN
AstraZeneca
Phase 2BB
Carboplatin
AbbVie
Phase 2/3BB
Indocyanine Green
Istanbul University
Phase 4BB
Ringer's acetate
Joachim Zdolsek
Phase 4B
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Adavosertib is also rated in:

refractory malignant neoplasmActive
B
Indicative · Phase 2
62 / 100
View asset →
exocrine pancreatic carcinomaActive
B
Indicative · Phase 2
59 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative · Phase 2
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →